NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Dunad Therapeutics

Dunad Therapeutics

Private
CambridgeHealthcare & Life Scienceshttps://www.dunadtx.com/

Last Round

Strategic

Nov 2, 2021

Total Funding Raised

$30.9M

Company Overview

Dunad Therapeutics is a biotechnology company that develops next-generation targeted oral protein degradation therapies for oncology and CNS indications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

targeted protein degradationcovalent chemistryTPDdrug discovery platformundruggable targetssmall molecule drugscovalent degradersmolecular glueneurodegenerative diseaseCNS-accessible drugsmono-valent degradersoral medicinesbiotech partnershipsoncologydrug licensingALS therapyParkinson's disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Dunad Therapeutics Comparables

Compare Dunad Therapeutics with similar companies based on industry and business-model similarity.

Dunad Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
RDP Pharma AG
87%
Plexium
86%
Amphista Therapeutics
85%

Dunad Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicNov 2, 2021
SeedMar 23, 2021

Key People

Founding team and executive leadership

Pearl Huang

CEO and President

Executive Team

Dunad Therapeutics Investors

Notable investors and investment history

Dunad Therapeutics investors
InvestorRounds
Epidarex CapitalStrategic, Seed
BioGeneration VenturesStrategic

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 4, 2025

    Monthly visitors increased 52% MoM.

  • Oct 22, 2023

    Grew 24% QoQ, from 25 to 31 employees.

Dunad Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Dunad Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Dunad Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range13
Year Founded2020
Last FundingNov 2, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.